Abeona Therapeutics® Announces First Patient Treatment with ZEVASKYN® Gene Therapy

Core Insights - Abeona Therapeutics Inc. has announced the first commercial patient treatment with its FDA-approved gene therapy ZEVASKYN, aimed at treating wounds in patients with recessive dystrophic epidermolysis bullosa (RDEB) [1][2] - ZEVASKYN is the first and only autologous cell sheet-based gene therapy for RDEB, which is characterized by severe skin wounds due to a defect in the COL7A1 gene [4][5] - The treatment has shown clinically meaningful wound healing and pain reduction with a single surgical application [4] Company Overview - Abeona Therapeutics is a commercial-stage biopharmaceutical company focused on developing cell and gene therapies for serious diseases, with ZEVASKYN being a key product in its portfolio [8] - The company operates a fully integrated cGMP manufacturing facility in Cleveland, Ohio, which is responsible for the commercial production of ZEVASKYN [8] Treatment Details - ZEVASKYN incorporates the COL7A1 gene into a patient's skin cells to produce functional type VII collagen, essential for skin integrity [4] - The therapy is indicated for both adult and pediatric patients suffering from RDEB [5] - Abeona Assist® is a comprehensive patient support program that helps patients understand insurance benefits and provides logistical assistance [2]